Immuneering Corporation — Q2 2023 Form 10-Q
Business context and reporting period. This clinical-stage oncology company reported for the quarter and six months ended June 30, 2023. Its lead candidate, IMM-1-104, is in a Phase 1/2a trial for advanced solid tumors with RAS mutations. The company has discontinued its legacy computational biology services and external biosample-storage businesses and does not expect to enter new service contracts.
Financial results and liquidity
| Metric | Three months ended June 30, 2023 | Prior-year period | Six months ended June 30, 2023 | Prior-year period |
|---|---|---|---|---|
| Revenue | $0 | $94,419 | $0 | $278,117 |
| Research and development expense | $9.45 million | $7.98 million | $19.66 million | $17.03 million |
| General and administrative expense | $4.04 million | $3.70 million | $8.51 million | $7.66 million |
| Net loss | $12.19 million | $11.53 million | $25.79 million | $24.42 million |
| Basic and diluted loss per share | $0.43 | $0.44 | $0.94 | $0.93 |
- Revenue and cost of revenue were zero in 2023; gross margin is therefore not meaningful. Prior-year revenue came from discontinued services and storage contracts.
- Operating expenses rose 15.5% in Q2 and 14.1% in the first half year over year. Management attributed the increase primarily to higher R&D spending, including IMM-1-104, and higher professional fees and stock-based compensation.
- Interest income was $1.17 million in Q2 and $2.00 million for the first half, up from $0.14 million and $0.28 million, respectively, mainly reflecting higher interest rates.
- At June 30, cash and cash equivalents were $104.02 million and current marketable securities were $4.97 million, totaling approximately $108.99 million in liquid resources. Current assets were $111.51 million and current liabilities $5.48 million.
- First-half operating cash use was $25.17 million, compared with $21.73 million in 2022. Investing activities provided $28.14 million, primarily from maturities of marketable securities; financing activities provided $28.41 million.
- The company raised approximately $28.2 million in an April follow-on offering, issuing 2,727,273 shares at $11 per share. Class A shares outstanding increased to 29,263,028 at quarter-end from 26,418,732 at year-end 2022.
- No borrowings are reported. Lease liabilities totaled $4.64 million, including $0.33 million current and $4.31 million noncurrent; future minimum lease payments were $7.11 million before imputed interest.
Changes, outlook, and risks
- Clinical progress: In June, the safety review committee found doses up to and including 320 mg once daily tolerable, with no dose-limiting toxicities observed in the dose-escalation portion of the IMM-1-104 trial. The company began Phase 1b evaluation of 240 mg and 320 mg once-daily cohorts, approximately 12 patients each.
- Milestones: Subject to Phase 1b completion and results, management planned to announce a recommended Phase 2 dose in early 2024. It planned to submit an IND for IMM-6-415 in Q4 2023; that candidate was in IND-enabling studies.
- Cash outlook: Management said existing cash, cash equivalents, and marketable securities were expected to fund development and operations into 2025, subject to assumptions that could prove incorrect. The financial-statement note separately states management expected resources to cover at least 12 months from issuance and concluded there was no substantial doubt about going concern.
- Operating outlook: The company expects continued losses and increased R&D, G&A, and capital expenditures. It does not expect product revenue for several years, if at all, and says additional capital may be needed beyond its current runway.
- Key risks and contingencies: Clinical and regulatory outcomes remain uncertain; early-stage results may not predict later trials. Other material risks include patient enrollment, safety, third-party manufacturing and CRO dependence, intellectual-property protection, and the need for additional financing. The company reported no material legal proceedings and no material off-balance-sheet arrangements.
Investor facts to verify
- Review subsequent IMM-1-104 safety, enrollment, and dose-evaluation disclosures, including whether the planned Phase 2 dose timing changed.
- Check whether the planned IMM-6-415 IND submission occurred and whether it led to authorization to begin clinical testing.
- Compare subsequent cash burn and financing with the stated runway into 2025; note that management’s estimate depends on assumptions.
- Track dilution from outstanding options: 5,453,392 options were outstanding at June 30, 2023, in addition to the shares issued in the follow-on offering.
- Monitor clinical-trial, manufacturing, regulatory, and financing risks, as well as the company’s lease commitments.